Pharmacokinetics of high dose etoposide (VP 16–213)

Etoposide (VP-16–213)

1985 • 361 citations

Noncompartmental Determination of the Steady-State Volume of Distribution for Any Mode of Administration

1982 • 288 citations

Clinical Pharmacokinetics of Hydralazine

1982 • 155 citations

Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients.

1984 • 149 citations

The podophyllotoxin derivatives VP16-213 and VM26

1982 • 146 citations

Etoposide (VP-16): Current Status and New Developments

1985 • 143 citations

Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives

1975 • 109 citations

High-dose VP-16-213 and autologous bone marrow transplantation for refractory malignancies: a phase I study.

1983 • 107 citations

Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer

1982 • 107 citations

Penetration of VP 16-213 into cerebrospinal fluid after high-dose intravenous administration.

1984 • 77 citations

EPEG, a new antineoplastic epipodophyllotoxin

1975 • 64 citations

Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study

1984 • 44 citations

Plasma assay for the antineoplastic agent VP 16-213 (etoposide) using high-performance liquid chromatography with electrochemical detection

1983 • 38 citations

ETOPOSIDE: A NEW ANTI-CANCER AGENT

1981 • 26 citations

Phase I clinical trial of weekly administration of 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213).

1974 • 23 citations

Pharmacokinetics of etoposide in gestochoriocarcinoma.

1985 • 23 citations

Metabolic studies of a podophyllotoxin derivative (VP16) in the isolated perfused liver

1985 • 18 citations

Clinical pharmacokinetics of VP16

1982 • 5 citations

Nonlinear regression on multiple-dose data

1979 • 3 citations